|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Foo M and Leong T: Adjuvant therapy for
gastric cancer: Current and future directions. World J
Gastroenterol. 20:13718–13727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park SC and Chun HJ: Chemotherapy for
advanced gastric cancer: Review and update of current practices.
Gut Liver. 7:385–393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao Q, Zhang H, Li Y, Liu J, Hu X and Fan
L: Anti-tumor effects of CIK combined with oxaliplatin in human
oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J
Exp Clin Cancer Res. 29:1182010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang J, Zhou XQ, Li JY, Cheng JF, Zeng XN,
Li X and Liu P: Prognostic significance of ERCC1 expression in
postoperative patients with gastric cancer. Chin J Cancer Res.
26:323–330. 2014.PubMed/NCBI
|
|
7
|
Yao A, Wang Y, Peng X, Ye R, Wang Q, Qi Y
and Zhou F: Predictive value of excision repair
cross-complementation group 1 expression for platinum-based
chemotherapy and survival in gastric cancer: A meta-analysis. J
Cancer Res Clin Oncol. 140:2107–2117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lih CJ, Wei W and Cohen SN: Txr1: A
transcriptional regulator of thrombospondin-1 that modulates
cellular sensitivity to taxanes. Genes Dev. 20:2082–2095. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Papadaki C, Mavroudis D, Trypaki M,
Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki1 E,
Georgoulias V and Souglakos J: Tumoral expression of TXR1 and TSP1
predicts overall survival of patients with lung adenocarcinoma
treated with first-line docetaxel-gemcitabine regimen. Clin Cancer
Res. 15:3827–3833. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bai Z, Zhang Z, Qu X, Han W and Ma X:
Sensitization of breast cancer cells to taxol by inhibition of
taxol resistance gene 1. Oncol Lett. 3:135–140. 2012.PubMed/NCBI
|
|
11
|
Bai ZG, Qu X, Han W, Ma XM, Zhao XM and
Zhang ZT: Expression of taxol resistance gene 1 correlates with
gastric cancer patient clinical outcome and induces taxol
resistance. Mol Med Rep. 3:1071–1078. 2010.PubMed/NCBI
|
|
12
|
Waddell T, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D: European Society for Medical Oncology
(ESMO); European Society of Surgical Oncology (ESSO); European
Society of Radiotherapy and Oncology (ESTRO): ESMO; ESSO; ESTRO:
Gastric cancer: cancer: Gastric cancer: ESMO-ESSO-ESTRO clinical
practice guidelines for diagnosis, treatment and follow-up. J Eur J
Surg Oncol. 40:584–591. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
GASTRIC (Global Advanced/Adjuvant Stomach
Tumor Research International Collaboration) Group. Paoletti X, Oba
K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P,
Sakamoto J, Sargent D, Sasako M, et al: Benefit of adjuvant
chemotherapy for resectable gastric cancer: A meta-analysis. JAMA.
303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Waddell T, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D: European Society for Medical Oncology
(ESMO); European Society of Surgical Oncology (ESSO); and European
Society of Radiotherapy and Oncology (ESTRO): Gastric cancer:
ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 24(Suppl 6): vi57–vi63. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alian OM, Azmi AS and Mohammad RM: Network
insights on oxaliplatin anti-cancer mechanisms. Clin Transl Med.
1:262012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Noh SH, Park SR, Yang HK, Chung HC, Chung
IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, et al: CLASSIC trial
investigators: Adjuvant capecitabine plus oxaliplatin for gastric
cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an
open-label, randomised phase 3 trial. Lancet Oncol. 15:1389–1396.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Di Francia R, Siesto RS, Valente D, Del
Buono A, Pugliese S, Cecere S, Cavaliere C, Nasti G, Facchini G and
Berretta M: Current strategies to minimize toxicity of oxaliplatin:
Selection of pharmacogenomic panel tests. Anticancer Drugs.
24:1069–1078. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bi J, Bai Z, Ma X, Song J, Guo Y, Zhao J,
Yi X, Han S and Zhang Z: Txr1: An important factor in oxaliplatin
resistance in gastric cancer. Med Oncol. 31:8072014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sid B, Sartelet H, Bellon G, El Btaouri H,
Rath G, Delorme N, Haye B and Martiny L: Thrombospondin. 1 A
multifunctional protein implicated in the regulation of tumor
growth. Crit Rev Oncol Hematol. 49:245–258. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Amerongen R and Berns A: TXR1-mediated
thrombospondin repression: A novel mechanism of resistance to
taxanes? Genes Dev. 20:1975–1981. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Papadaki C, Tsaroucha E, Kaklamanis L,
Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E,
Georgoulias V and Souglakos J: Correlation of BRCA1, TXR1 and TSP1
mRNA expression with treatment outcome to docetaxel-based
first-line chemotherapy in patients with advanced/metastatic
non-small-cell lung cancer. Br J Cancer. 104:316–323. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo W, Dong Z, He M, Guo Y, Guo J, Chen Z,
Yang Z and Kuang G: Aberrant methylation of thrombospondin-1 and
its association with reduced expression in gastric cardia
adenocarcinoma. J Biomed Biotechnol. 2010:7214852010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Reardon JT, Vaisman A, Chaney SG and
Sancar A: Efficient nucleotide excision repair of cisplatin,
oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum
(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res.
59:3968–3971. 1999.PubMed/NCBI
|
|
24
|
Deng Q, Yang H, Lin Y, Qiu Y, Gu X, He P,
Zhao M, Wang H, Xu Y, Lin Y, et al: Prognostic value of ERCC1 mRNA
expression in non-small cell lung cancer, breast cancer, and
gastric cancer in patients from Southern China. Int J Clin Exp
Pathol. 7:8312–8321. 2014.PubMed/NCBI
|
|
25
|
Lee KB, Parker RJ, Bohr V, Cornelison T
and Reed E: Cisplatin sensitivity/resistance in UV repair-deficient
Chinese hamster ovary cells of complementation groups 1 and 3.
Carcinogenesis. 14:2177–2180. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Melton DW, Ketchen AM, Núñez F,
Bonatti-Abbondandolo S, Abbondandolo A, Squires S and Johnson RT:
Cells from ERCC1-deficient mice show increased genome instability
and a reduced frequency of S-phase-dependent illegitimate
chromosome exchange but a normal frequency of homologous
recombination. J Cell Sci. 111:395–404. 1998.PubMed/NCBI
|
|
27
|
Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY,
Chung MH and You HJ: Oncogenic H-Ras up-regulates expression of
ERCC1 to protect cells from platinum-based anticancer agents.
Cancer Res. 64:4849–4857. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Metzger R, Leichman CG, Danenberg KD,
Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H,
Laine L, et al: ERCC1 mRNA levels complement thymidylate synthase
mRNA levels in predicting response and survival for gastric cancer
patients receiving combination cisplatin and fluorouracil
chemotherapy. J Clin Oncol. 16:309–316. 1998.PubMed/NCBI
|
|
29
|
Reed E: Platinum-DNA adduct, nucleotide
excision repair and platinum based anti-cancer chemotherapy. Cancer
Treat Rev. 24:331–344. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wood RD, Mitchell M, Sgouros J and Lindahl
T: Human DNA repair genes. Science. 291:1284–1289. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reed E, Yu JJ, Davies A, Gannon J and
Armentrout SL: Clear cell tumors have higher mRNA levels of ERCC1
and XPB than other histological types of epithelial ovarian cancer.
Clin Cancer Res. 9:5299–5305. 2003.PubMed/NCBI
|
|
32
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
